Nontype 1 ROP with some characteristics, such as preplus, ridge aggravation, treatment with contralateral eyes, no regression in the persistent stage 2 or 3 for follow-up ≥ PMA 44 weeks, and logistical considerations, can be considered carefully to receive intravitreal injection of anti-VEGF drugs based on current expert consensus or guidelines. Here, VEGFA is linked to retinopathy of prematurity.